ArticleMedComm2025

Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.

Jianli Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.